# Novo Nordisk Halts Two Cardiovascular Trials for Inflammation-Targeting Drug

Novo Nordisk has stopped two clinical trials testing a drug designed to lower inflammation as a way to improve cardiovascular health. The company’s decision marks another setback for this treatment approach.

The drug in question, ziltivekimab, was being evaluated for its ability to reduce inflammation and lower the risk of cardiovascular events. The trials were stopped based on data reviewed by the study’s independent monitoring committee, though specific reasons were not disclosed in the available summary.

The news follows a broader trend of difficulty in developing therapies that target inflammation to treat heart disease. Several other pharmaceutical companies have faced similar challenges in this area of drug development.

**Context for the life sciences**

The role of inflammation in cardiovascular disease has become a major focus of biomedical research. Chronic low-grade inflammation is now understood to contribute to atherosclerosis, heart attacks, and strokes. Drugs that block specific inflammatory pathways, such as interleukin-6 or tumor necrosis factor, have shown promise in some studies but have also failed in others due to safety concerns or lack of efficacy. This trial halt underscores the complexity of translating insights about inflammation into safe, effective therapies. For animal science and veterinary medicine, similar inflammatory pathways are relevant in conditions like equine laminitis and canine heart disease, making human trial results informative across species.

Source: [STAT News report](https://www.statnews.com/2026/09/07/novo-nordisk-heart-studies-inflammation-ziltivekimab/?utm_campaign=rss)